Celldex Therapeutics (CLDX) Competitors $22.59 -0.46 (-2.00%) Closing price 02/20/2025 04:00 PM EasternExtended Trading$22.38 -0.21 (-0.93%) As of 02/20/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CLDX vs. ALKS, IONS, FOLD, LGND, BCRX, DVAX, GERN, MNKD, MYGN, and NVAXShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), Geron (GERN), MannKind (MNKD), Myriad Genetics (MYGN), and Novavax (NVAX). These companies are all part of the "biotechnology" industry. Celldex Therapeutics vs. Alkermes Ionis Pharmaceuticals Amicus Therapeutics Ligand Pharmaceuticals BioCryst Pharmaceuticals Dynavax Technologies Geron MannKind Myriad Genetics Novavax Alkermes (NASDAQ:ALKS) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends. Do analysts recommend ALKS or CLDX? Alkermes currently has a consensus target price of $38.36, suggesting a potential upside of 8.07%. Celldex Therapeutics has a consensus target price of $60.22, suggesting a potential upside of 166.59%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Which has more risk & volatility, ALKS or CLDX? Alkermes has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Is ALKS or CLDX more profitable? Alkermes has a net margin of 23.57% compared to Celldex Therapeutics' net margin of -1,544.32%. Alkermes' return on equity of 30.80% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.57% 30.80% 19.09% Celldex Therapeutics -1,544.32%-19.75%-18.86% Which has better earnings and valuation, ALKS or CLDX? Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.71$367.07M$2.1716.36Celldex Therapeutics$6.88M217.82-$141.43M-$2.57-8.79 Do institutionals & insiders hold more shares of ALKS or CLDX? 95.2% of Alkermes shares are owned by institutional investors. 4.9% of Alkermes shares are owned by insiders. Comparatively, 3.8% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor ALKS or CLDX? Alkermes received 80 more outperform votes than Celldex Therapeutics when rated by MarketBeat users. However, 75.27% of users gave Celldex Therapeutics an outperform vote while only 70.52% of users gave Alkermes an outperform vote. CompanyUnderperformOutperformAlkermesOutperform Votes70170.52% Underperform Votes29329.48% Celldex TherapeuticsOutperform Votes62175.27% Underperform Votes20424.73% Does the media prefer ALKS or CLDX? In the previous week, Alkermes had 9 more articles in the media than Celldex Therapeutics. MarketBeat recorded 20 mentions for Alkermes and 11 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.67 beat Alkermes' score of 0.48 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 7 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celldex Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAlkermes beats Celldex Therapeutics on 11 of the 18 factors compared between the two stocks. Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53B$2.20B$5.80B$9.11BDividend YieldN/A0.74%5.28%3.98%P/E RatioN/A5.0825.2618.83Price / Sales217.8286.88473.04119.70Price / CashN/A15.8545.1138.19Price / Book2.493.327.675.13Net Income-$141.43M-$65.73M$3.18B$245.96M7 Day Performance-0.48%-1.87%-0.50%-0.89%1 Month Performance-8.21%-7.18%1.84%-0.51%1 Year Performance-40.11%-13.51%18.75%16.50% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics1.3799 of 5 stars$22.59-2.0%$60.22+166.6%-41.3%$1.53B$6.88M0.00150ALKSAlkermes3.7259 of 5 stars$35.89-0.3%$37.25+3.8%+16.8%$5.81B$1.66B18.412,100IONSIonis Pharmaceuticals4.3158 of 5 stars$31.04+2.3%$60.65+95.4%-26.3%$4.90B$788M-12.72800Earnings ReportAnalyst ForecastNews CoverageFOLDAmicus Therapeutics3.8516 of 5 stars$9.77+1.3%$16.88+72.7%-33.8%$2.92B$399.36M-28.74480Analyst DowngradeNews CoverageLGNDLigand Pharmaceuticals4.2056 of 5 stars$120.00+5.3%$147.00+22.5%+68.6%$2.27B$131.31M47.8180Positive NewsBCRXBioCryst Pharmaceuticals3.9827 of 5 stars$9.05+2.6%$15.50+71.3%+61.3%$1.87B$331.41M-14.84530High Trading VolumeDVAXDynavax Technologies4.225 of 5 stars$12.82+1.0%$21.50+67.7%+8.6%$1.69B$232.28M98.62350Earnings ReportNews CoverageGERNGeron3.2417 of 5 stars$2.56-8.2%$7.25+183.2%+34.1%$1.55B$240,000.00-8.0070Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeMNKDMannKind2.8574 of 5 stars$5.42-2.3%$9.21+70.0%+57.2%$1.49B$198.96M77.43400MYGNMyriad Genetics4.0063 of 5 stars$14.56-0.6%$22.54+54.8%-36.3%$1.33B$753.20M-11.202,700Analyst DowngradeNVAXNovavax4.1469 of 5 stars$8.19+0.1%$17.83+117.7%+91.8%$1.31B$983.71M-3.621,543 Related Companies and Tools Related Companies Alkermes Alternatives Ionis Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Ligand Pharmaceuticals Alternatives BioCryst Pharmaceuticals Alternatives Dynavax Technologies Alternatives Geron Alternatives MannKind Alternatives Myriad Genetics Alternatives Novavax Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLDX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
